Oramed Pharmaceuticals Inc.
ORMPHealthcare|Biotechnology|US
$3.86
-0.03 (-0.77%)
DCF Value
$1.17
Tangible Book / Share
$7.74
Graham Number
$27.23
Cash / Share
$1.23
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04754334 A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | T2DM (Type 2 Diabetes Mellitus) | P3 | Terminated | 346 | RCT, Double-blind | ORMD-0801 |
| NCT04606576 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P3 | Terminated | 710 | RCT, Double-blind | ORMD-0801 QD, ORMD-0801 BD |
| NCT04817215 Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Unknown | 608 | RCT, Double-blind | ORMD-0801 |
| NCT06731075 A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | Type 2 Diabetes Mellitus | P3 | Not Yet Recruiting | 300 | RCT, Double-blind | ORMD-0801 8 mg, ORMD-0801 16 mg |
| NCT02094534 A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics | Diabetes Mellitus Type 1 | P2 | Completed | 25 | RCT, Double-blind | ORMD-0801 Capsules |
| NCT04564846 A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P2 | Completed | 49 | RCT, Double-blind | ORMD-0801 |
| NCT02535715 A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED) | Type 1 Diabetes | P2 | Completed | 11 | Open-label | ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg |
| NCT04616014 A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis (NASH) | P2 | Completed | 7 | Open-label | ORMD-0801 QD |
| NCT02496000 Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus | Diabetes Type 2 | P2 | Completed | 188 | RCT, Double-blind | ORMD-0801, Placebo Comparator |
| NCT02653300 A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis (NASH), Type2 Diabetes Mellitus | P2 | Completed | 10 | Open-label | Oral Insulin |
| NCT01889667 Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus Type 2 | P2 | Completed | 30 | RCT, Double-blind | ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo |
| NCT03467932 A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus | T2DM (Type 2 Diabetes Mellitus) | P2 | Completed | 373 | RCT, Double-blind | Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801 |
| NCT00867594 Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients | Brittle Type I Diabetes Mellitus | P2 | Completed | 12 | Open-label | ORMD 0801 |
| NCT04618744 A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | P2 | Completed | 32 | RCT, Double-blind | ORMD-0801 (Insulin) capsule 8 mg BD |
| NCT02954601 A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P2 | Completed | 31 | RCT, Double-blind | ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid) |
| NCT04150107 A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes | Type 1 Diabetes | P2 | Completed | 30 | RCT, Open-label | ORMD-0801 Treatment A, ORMD-0801 Treatment B |